ORAL C5A RECEPTOR ANTAGONIST CCX168 IN A PHASE 2 CLINICAL TRIAL IN ANCA-ASSOCIATED RENAL VASCULITIS

被引：0

作者：

Bekker, Pirow ^{[1
]}

Potarca, Antonia ^{[1
]}

Dairaghi, Daniel ^{[1
]}

Miao, Shichang ^{[1
]}

Powers, Jay P. ^{[1
]}

Jaen, Juan C. ^{[1
]}

Schall, Thomas J. ^{[1
]}

机构：

[1] Chemocentryx Inc, Mountain View, CA USA

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2012年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

引用

页码：419 / 420

页数：2

共 41 条

[1] ORAL C5A RECEPTOR ANTAGONIST CCX168 PHASE 2 CLINICAL TRIAL IN ANCA-ASSOCIATED RENAL VASCULITIS
Jayne, D. R.
Bruchfeld, A.
Schaier, M.
Ciechanowski, K.
Harper, L.
Jadoul, M.
Segelmark, M.
Selga, D.
Szombati, I.
Venning, M.
Hugo, C.
Van Daele, P. L.
Viklicky, O.
Potarca, A.
Schall, T. J.
Bekker, P.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 148 - 148
[2] PHASE 2 RANDOMISED TRIAL OF ORAL C5A RECEPTOR ANTAGONIST CCX168 IN ANCA-ASSOCIATED RENAL VASCULITIS
Jayne, David R. W.
Bruchfeld, Annette
Schaier, Matthias
Ciechanowski, Kazimierz
Harper, Lorraine
Jadoul, Michel
Segelmark, Marten
Selga, Daina
Szombati, Istvan
Venning, Michael
Hamilton, Patrick
Hugo, Christian
Van Daele, Paul L. A.
Viklicky, Ondrej
Potarca, Antonia
Schall, Thomas J.
Bekker, Pirow
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 27 - 27
[3] CLINICAL DOSE SELECTION OF THE C5A RECEPTOR ANTAGONIST CCX168 FOR THE PHASE 2 ANCA-ASSOCIATED RENAL VASCULITIS CLINICAL TRIAL (THE CLEAR TRIAL)
Dairaghi, Daniel
Johnson, Daniel
Leleti, Manmohan
Miao, Shichang
Xiao, Hong
Jennette, J. Charles
Powers, Jay P.
Seitz, Lisa
Wang, Yu
Jaen, Juan C.
Schall, Thomas J.
Bekker, Pirow
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 401 - 402
[4] SUCCESSFUL STEROID REPLACEMENT IN ANCA-ASSOCIATED VASCULITIS WITH C5A RECEPTOR INHIBITOR CCX168 IN PHASE 2 RANDOMISED TRIAL (CLEAR)
Jayne, David
Bruchfeld, Annette
Harper, Lorraine
Schaier, Matthias
Venning, Michael
Hamilton, Patrick
Burst, Volker
Grundman, Franziska
Jadoul, Michel
Szombati, Istvan
Tesar, Vladimir
Segelmark, Marten
Potarca, Antonia
Schall, Thomas J.
Bekker, Pirow
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 45 - 45
[5] A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis
Merkel, Peter A.
Niles, John
Jimenez, Richard
Spiera, Robert F.
Rovin, Brad H.
Bomback, Andrew
Pagnoux, Christian
Potarca, Antonia
Schall, Thomas J.
Bekker, Pirow
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[6] C5aR inhibitor on leukocytes exploratory ANCA associated renal vasculitis (CLEAR) clinical trial with orally administered CCX168
Bruchfeld, A.
Schaier, M.
Jadoul, M.
Selga, D.
Szombati, I.
Venning, M.
Hamilton, P.
Ciechanowski, K.
Hugo, C.
Segelmark, M.
Viklicky, O.
Jaen, J.
Schall, T.
Bekker, P.
PRESSE MEDICALE, 2013, 42 (04): : 768 - 769
[7] C5A AND ITS RECEPTOR IN ANCA-ASSOCIATED VASCULITIS
Zhao, M. -H.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 32 - 33
[8] EFFECT OF A SELECTIVE C5AR ANTAGONIST, AVACOPAN (CCX168), ON PLASMA COMPLEMENT LEVELS IN ANCA ASSOCIATED VASCULITIS (AAV)
Bunch, D. O.
Deng, J.
McInnis, E. A.
Bekker, P.
Hillson, J. L.
Schall, T. J.
Jennette, C. J.
Nachman, P.
Deng, J.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 74 - 75
[9] Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
Jayne, David R. W.
Bruchfeld, Annette N.
Harper, Lorraine
Schaier, Matthias
Venning, Michael C.
Hamilton, Patrick
Burst, Volker
Grundmann, Franziska
Jadoul, Michel
Szombati, Istvan
Tesar, Vladimir
Segelmark, Marten
Potarca, Antonia
Schall, Thomas J.
Bekker, Pirow
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (09): : 2756 - 2767
[10] The Effect on Renal Function of the Complement C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
Merkel, Peter
Bekker, Pirow
Yue, Huibin
Kelleher, Catherine
Schall, Thomas
Jayne, David
ARTHRITIS & RHEUMATOLOGY, 2020, 72

← 1 2 3 4 5 →